<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754974</url>
  </required_header>
  <id_info>
    <org_study_id>AI452-033</org_study_id>
    <secondary_id>2012-003508-11</secondary_id>
    <nct_id>NCT01754974</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C</brief_title>
  <acronym>BASIS</acronym>
  <official_title>A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda
      plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to
      therapy with Peginterferon alfa-2a plus Ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, and/or neutropenia as defined by ANC &lt; 750 mm3 and/or thrombocytopenia as defined by platelets &lt; 50,000 mm3) in treatment-naive subjects</measure>
    <time_frame>Up to 48 weeks of treatment</time_frame>
    <description>ANC = Absolute Neutrophil Count
Hb = Hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Sustained Virologic Response at Post-Treatment Follow-up Week 24 (SVR24), defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt; Lower Limit of Quantitation of Assay (LLOQ)</measure>
    <time_frame>At Post-Treatment Follow-up Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Rapid Virologic Response (RVR) (HCV RNA not detected)</measure>
    <time_frame>On treatment Week 4 (of an up to 48-week treatment period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with on-treatment Serious Adverse Events (SAEs) through end of treatment</measure>
    <time_frame>Up to 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with dose reductions through end of treatment</measure>
    <time_frame>Up to 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinue due to Adverse Events (AEs) through end of treatment</measure>
    <time_frame>Up to 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with on-treatment Interferon (IFN)-associated symptoms as determined by adverse event reporting</measure>
    <time_frame>Up to 48 weeks of treatment</time_frame>
    <description>On-treatment IFN-associated symptoms are:
Flu-like symptoms (as defined by pyrexia or chills or pain)
Musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)
Neurological symptoms (headache or dizziness)
Constitutional symptoms (fatigue or asthenia)
Psychiatric symptoms (depression or irritability or insomnia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Peginterferon Lambda-1a + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a + Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon Lambda-1a</intervention_name>
    <arm_group_label>Peginterferon Lambda-1a + Ribavirin</arm_group_label>
    <other_name>BMS-914143</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>Peginterferon Lambda-1a + Ribavirin</arm_group_label>
    <arm_group_label>Peginterferon alfa-2a + Ribavirin</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <arm_group_label>Peginterferon alfa-2a + Ribavirin</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C, Genotype 1

          -  HCV RNA ≥100,000 IU/mL at screening

          -  Liver biopsy documenting no cirrhosis (within prior 3 years). Where approved for
             staging of liver disease, non-invasive imaging may be used to assess the extent of
             liver disease

          -  Naïve to prior anti-HCV therapy

        Exclusion Criteria:

          -  Infected with HCV other than Genotype 1

          -  Positive Hepatitis B Surface Antigen (HBsAg), or Human Immunodeficiency Virus
             (HIV)-1/HIV-2 antibody at screening

          -  Evidence of liver disease other than HCV

          -  Active substance abuse

          -  Use of hematologic growth factors within 90 days prior to study randomization

          -  Evidence of history of cirrhosis based on radiologic criteria or biopsy results and
             clinical criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Usti Nad Labem</city>
        <zip>400 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chungcheongnam-do</city>
        <zip>330-930</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daegu</city>
        <zip>700-821</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gangwon-do</city>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyeongsangnam-do</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico City</city>
        <state>Estado De Mexico</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Distrito Federal</city>
        <zip>03720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

